Skip to main content
Top
Published in: Journal of Clinical Immunology 6/2015

01-08-2015 | Brief Communication

Profound Reversible Hypogammaglobulinemia Caused by Celiac Disease in the Absence of Protein Losing Enteropathy

Authors: Rohan Ameratunga, Russell William Barker, Richard Henderson Steele, Maneka Deo, See-Tarn Woon, Mee Ling Yeong, Wikke Koopmans

Published in: Journal of Clinical Immunology | Issue 6/2015

Login to get access

Abstract

When patients with hypogammaglobulinemia are encountered, a vigorous search should be undertaken for secondary treatable causes. Here we describe the first case of a patient with severe asymptomatic hypogammaglobulinemia where the underlying cause was undiagnosed celiac disease. A strict gluten free diet resulted in resolution of her mild long-standing abdominal symptoms and correction of her hypogammaglobulinemia. There was corresponding improvement in her duodenal histology and normalisation of her celiac serology. Protein losing enteropathy was unlikely to have been the mechanism of her profound hypogammaglobulinemia, as her albumin was within the normal range and she had a normal fecal alpha 1 antitrypsin level. Application of the Ameratunga et al. (2013) diagnostic criteria was helpful in confirming this patient did not have Common Variable Immunodeficiency Disorder (CVID). Celiac disease must now be considered in the differential diagnosis of severe hypogammaglobulinemia. There should be a low threshold for undertaking celiac serology in patients with hypogammaglobulinemia, even if they have minimal symptoms attributable to gut disease.
Literature
1.
go back to reference Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108(5):656–76. quiz 77.PubMedPubMedCentralCrossRef Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108(5):656–76. quiz 77.PubMedPubMedCentralCrossRef
2.
go back to reference Hope BC, Ameratunga R, Austin PM, Evans HM, MacFarlane J, Mouat S, et al. Diagnostic utility of modified gliadin peptide antibody assays in New Zealand children. J Pediatr Gastroenterol Nutr. 2013;57(1):43–8.PubMedCrossRef Hope BC, Ameratunga R, Austin PM, Evans HM, MacFarlane J, Mouat S, et al. Diagnostic utility of modified gliadin peptide antibody assays in New Zealand children. J Pediatr Gastroenterol Nutr. 2013;57(1):43–8.PubMedCrossRef
3.
go back to reference Steele R. Diagnosis and management of coeliac disease in children. Postgrad Med J. 2011;87(1023):19–25.PubMedCrossRef Steele R. Diagnosis and management of coeliac disease in children. Postgrad Med J. 2011;87(1023):19–25.PubMedCrossRef
4.
go back to reference Abu-Zekry M, Kryszak D, Diab M, Catassi C, Fasano A. Prevalence of celiac disease in Egyptian children disputes the east–west agriculture-dependent spread of the disease. J Pediatr Gastroenterol Nutr. 2008;47(2):136–40.PubMedCrossRef Abu-Zekry M, Kryszak D, Diab M, Catassi C, Fasano A. Prevalence of celiac disease in Egyptian children disputes the east–west agriculture-dependent spread of the disease. J Pediatr Gastroenterol Nutr. 2008;47(2):136–40.PubMedCrossRef
5.
go back to reference Sood A, Midha V, Sood N, Avasthi G, Sehgal A. Prevalence of celiac disease among school children in Punjab, North India. J Gastroenterol Hepatol. 2006;21(10):1622–5.PubMedCrossRef Sood A, Midha V, Sood N, Avasthi G, Sehgal A. Prevalence of celiac disease among school children in Punjab, North India. J Gastroenterol Hepatol. 2006;21(10):1622–5.PubMedCrossRef
6.
go back to reference Malamut G, Verkarre V, Suarez F, Viallard JF, Lascaux AS, Cosnes J, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol. 2010;105(10):2262–75.PubMedCrossRef Malamut G, Verkarre V, Suarez F, Viallard JF, Lascaux AS, Cosnes J, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol. 2010;105(10):2262–75.PubMedCrossRef
7.
go back to reference Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203–11.PubMedPubMedCentral Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203–11.PubMedPubMedCentral
8.
go back to reference Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for CVID. Expert Rev Clin Immunol. 2014;10(2):183–6.PubMedCrossRef Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for CVID. Expert Rev Clin Immunol. 2014;10(2):183–6.PubMedCrossRef
9.
go back to reference Ameratunga RLK, Woon S-T, Jordan A, Anderson NE, Koopmans W. New diagnostic criteria could distinguish common variable immunodeficiency disorder from anticonvulsant-induced hypogammaglobulinemia. Clin Exp Neuroimmunol 2014;6(1):83–8.CrossRef Ameratunga RLK, Woon S-T, Jordan A, Anderson NE, Koopmans W. New diagnostic criteria could distinguish common variable immunodeficiency disorder from anticonvulsant-induced hypogammaglobulinemia. Clin Exp Neuroimmunol 2014;6(1):83–8.CrossRef
10.
go back to reference Ameratunga R. V, Casey P, Parry S, Kendi C.Hypogammaglobulinemia factitia. Munchausen syndrome presenting as Common Variable Immune Deficiency. Allergy Asthma Clin Immunol 2013;9(36). Ameratunga R. V, Casey P, Parry S, Kendi C.Hypogammaglobulinemia factitia. Munchausen syndrome presenting as Common Variable Immune Deficiency. Allergy Asthma Clin Immunol 2013;9(36).
11.
go back to reference Luzi G, Zullo A, Iebba F, Rinaldi V, Sanchez Mete L, Muscaritoli M, et al. Duodenal pathology and clinical-immunological implications in common variable immunodeficiency patients. Am J Gastroenterol. 2003;98(1):118–21.PubMedCrossRef Luzi G, Zullo A, Iebba F, Rinaldi V, Sanchez Mete L, Muscaritoli M, et al. Duodenal pathology and clinical-immunological implications in common variable immunodeficiency patients. Am J Gastroenterol. 2003;98(1):118–21.PubMedCrossRef
12.
go back to reference Kalha I, Sellin JH. Common variable immunodeficiency and the gastrointestinal tract. Curr Gastroenterol Rep. 2004;6(5):377–83.PubMedCrossRef Kalha I, Sellin JH. Common variable immunodeficiency and the gastrointestinal tract. Curr Gastroenterol Rep. 2004;6(5):377–83.PubMedCrossRef
13.
go back to reference Khodadad A, Aghamohammadi A, Parvaneh N, Rezaei N, Mahjoob F, Bashashati M, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci. 2007;52(11):2977–83.PubMedCrossRef Khodadad A, Aghamohammadi A, Parvaneh N, Rezaei N, Mahjoob F, Bashashati M, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci. 2007;52(11):2977–83.PubMedCrossRef
14.
go back to reference Biagi F, Bianchi PI, Zilli A, Marchese A, Luinetti O, Lougaris V, et al. The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: a clinical and histopathologic study. Am J Clin Pathol. 2012;138(2):185–9.PubMedCrossRef Biagi F, Bianchi PI, Zilli A, Marchese A, Luinetti O, Lougaris V, et al. The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: a clinical and histopathologic study. Am J Clin Pathol. 2012;138(2):185–9.PubMedCrossRef
15.
go back to reference Venhoff N, Emmerich F, Neagu M, Salzer U, Koehn C, Driever S, et al. The role of HLA DQ2 and DQ8 in dissecting celiac-like disease in common variable immunodeficiency. J Clin Immunol. 2013;33(5):909–16.PubMedCrossRef Venhoff N, Emmerich F, Neagu M, Salzer U, Koehn C, Driever S, et al. The role of HLA DQ2 and DQ8 in dissecting celiac-like disease in common variable immunodeficiency. J Clin Immunol. 2013;33(5):909–16.PubMedCrossRef
16.
go back to reference Bright P, Lock RJ, Unsworth DJ. Immunoglobulin A deficiency on serological coeliac screening: an opportunity for early diagnosis of hypogammaglobulinaemia. Ann Clin Biochem. 2012;49(Pt 5):503–4.PubMedCrossRef Bright P, Lock RJ, Unsworth DJ. Immunoglobulin A deficiency on serological coeliac screening: an opportunity for early diagnosis of hypogammaglobulinaemia. Ann Clin Biochem. 2012;49(Pt 5):503–4.PubMedCrossRef
18.
go back to reference Ameratuga R, Brewerton M, Slade C, Jordan A, Gillis D, Steele R, et al. Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front Immunol 2014;5:415. Ameratuga R, Brewerton M, Slade C, Jordan A, Gillis D, Steele R, et al. Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front Immunol 2014;5:415.
19.
go back to reference Carroccio A, Di Prima L, Noto D, Fayer F, Ambrosiano G, Villanacci V, et al. Searching for wheat plants with low toxicity in celiac disease: between direct toxicity and immunologic activation. Dig Liver Dis : Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2011;43(1):34–9.CrossRef Carroccio A, Di Prima L, Noto D, Fayer F, Ambrosiano G, Villanacci V, et al. Searching for wheat plants with low toxicity in celiac disease: between direct toxicity and immunologic activation. Dig Liver Dis : Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2011;43(1):34–9.CrossRef
20.
go back to reference Ameratunga R, Lindsay K, Woon S-T, Jordan A, Anderson NE, Koopmans W. New diagnostic criteria could distinguish common variable immunodeficiency disorder from anticonvulsant-induced hypogammaglobulinemia. Clin Exp Neuroimmunol 2014:n/a-n/a. Ameratunga R, Lindsay K, Woon S-T, Jordan A, Anderson NE, Koopmans W. New diagnostic criteria could distinguish common variable immunodeficiency disorder from anticonvulsant-induced hypogammaglobulinemia. Clin Exp Neuroimmunol 2014:n/a-n/a.
21.
go back to reference Oksenhendler E, Gerard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547–54.PubMedCrossRef Oksenhendler E, Gerard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547–54.PubMedCrossRef
22.
23.
go back to reference Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709–27.PubMedPubMedCentralCrossRef Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709–27.PubMedPubMedCentralCrossRef
24.
go back to reference Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5(2):156–9.PubMedCrossRef Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5(2):156–9.PubMedCrossRef
25.
go back to reference Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.PubMedCrossRef Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.PubMedCrossRef
26.
go back to reference Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–86.PubMedCrossRef Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–86.PubMedCrossRef
27.
go back to reference Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85.CrossRefPubMed Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85.CrossRefPubMed
28.
go back to reference Koopmans W, Woon ST, Zeng IS, Jordan A, Brothers S, Browett P, et al. Variability of memory B cell markers in a cohort of common variable immune deficiency patients over six months. Scand J Immunol 2013;77(6):470–5.PubMedCrossRef Koopmans W, Woon ST, Zeng IS, Jordan A, Brothers S, Browett P, et al. Variability of memory B cell markers in a cohort of common variable immune deficiency patients over six months. Scand J Immunol 2013;77(6):470–5.PubMedCrossRef
29.
go back to reference Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol. 2010;159(3):344–50.PubMedPubMedCentralCrossRef Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol. 2010;159(3):344–50.PubMedPubMedCentralCrossRef
30.
go back to reference Olinder-Nielsen AM, Granert C, Forsberg P, Friman V, Vietorisz A, Bjorkander J. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis. 2007;39(1):44–50.PubMedCrossRef Olinder-Nielsen AM, Granert C, Forsberg P, Friman V, Vietorisz A, Bjorkander J. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis. 2007;39(1):44–50.PubMedCrossRef
31.
go back to reference Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201(4):516–24.PubMedCrossRef Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201(4):516–24.PubMedCrossRef
32.
go back to reference Koopmans W, Woon ST, Brooks AE, Dunbar PR, Browett P, Ameratunga R. Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol. 2013;33(1):68–73.PubMedCrossRef Koopmans W, Woon ST, Brooks AE, Dunbar PR, Browett P, Ameratunga R. Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol. 2013;33(1):68–73.PubMedCrossRef
33.
go back to reference Tiller Jr TL, Buckley RH. Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. J Pediatr. 1978;92(3):347–53.PubMedCrossRef Tiller Jr TL, Buckley RH. Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. J Pediatr. 1978;92(3):347–53.PubMedCrossRef
34.
go back to reference Pan-Hammarstrom Q, Salzer U, Du L, Bjorkander J, Cunningham-Rundles C, Nelson DL, et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007;39(4):429–30.PubMedPubMedCentralCrossRef Pan-Hammarstrom Q, Salzer U, Du L, Bjorkander J, Cunningham-Rundles C, Nelson DL, et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007;39(4):429–30.PubMedPubMedCentralCrossRef
35.
go back to reference Salzer U, Bacchelli C, Buckridge S, Pan-Hammarstrom Q, Jennings S, Lougaris V, et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood. 2009;113(9):1967–76.PubMedPubMedCentralCrossRef Salzer U, Bacchelli C, Buckridge S, Pan-Hammarstrom Q, Jennings S, Lougaris V, et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood. 2009;113(9):1967–76.PubMedPubMedCentralCrossRef
36.
go back to reference Popa V. Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy. 1988;60(3):203–6.PubMed Popa V. Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy. 1988;60(3):203–6.PubMed
37.
go back to reference Ameratunga R, Becroft DM, Hunter W. The simultaneous presentation of sarcoidosis and common variable immune deficiency. Pathology. 2000;32(4):280–2.PubMedCrossRef Ameratunga R, Becroft DM, Hunter W. The simultaneous presentation of sarcoidosis and common variable immune deficiency. Pathology. 2000;32(4):280–2.PubMedCrossRef
38.
go back to reference Fasano MB, Sullivan KE, Sarpong SB, Wood RA, Jones SM, Johns CJ. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore). 1996;75(5):251–61.CrossRef Fasano MB, Sullivan KE, Sarpong SB, Wood RA, Jones SM, Johns CJ. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore). 1996;75(5):251–61.CrossRef
39.
go back to reference Fuss IJ, Friend J, Yang Z, He JP, Hooda L, Boyer J, et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol 2013. Fuss IJ, Friend J, Yang Z, He JP, Hooda L, Boyer J, et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol 2013.
40.
go back to reference Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard JF, Lascaux AS, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48(1):74–82.PubMedCrossRef Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard JF, Lascaux AS, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48(1):74–82.PubMedCrossRef
41.
go back to reference Agarwal S, Smereka P, Harpaz N, Cunningham-Rundles C, Mayer L. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis. 2011;17(1):251–9.PubMedCrossRef Agarwal S, Smereka P, Harpaz N, Cunningham-Rundles C, Mayer L. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis. 2011;17(1):251–9.PubMedCrossRef
Metadata
Title
Profound Reversible Hypogammaglobulinemia Caused by Celiac Disease in the Absence of Protein Losing Enteropathy
Authors
Rohan Ameratunga
Russell William Barker
Richard Henderson Steele
Maneka Deo
See-Tarn Woon
Mee Ling Yeong
Wikke Koopmans
Publication date
01-08-2015
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 6/2015
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-015-0189-6

Other articles of this Issue 6/2015

Journal of Clinical Immunology 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine